Treatment of latent tuberculosis with 12-weeks isoniazid/rifapentine in clinical practice

As part of the global End TB strategy [1–3] treatment of latent tuberculosis infection (LTBI) is now recommended in low endemic middle- and high income countries for certain risk groups, such as contacts of pulmonary TB, migrants from high endemic countries and immunocompromised individuals.Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Froberg has nothing to disclose.Conflict of interest: Dr. Jansson has nothing to disclose.Conflict of interest: Dr. Bruchfeld has nothing to disclose.